SK Bioscience

KSC:302440 · KR7302440003

BiotechnologySmall

360

Value45

Profit price81

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price33

Price/Sales28

EV / Gross Profit15

Price/Book55

Quality60

Returns on capital81

Return on Capital78

Cash Return on Capital80

Return on Equity85

Profit margins48

EBIT Margin53

Gross Profitability42

Cash backing53

Accruals34

Owner Earnings Margin71

Growth40

Sales growth53

Profit growth12

Reinvestment1

Price momentum48

Safety19

Debt load54

Debt serviceability13

Refinancing25

Debt Payback1

Liquidity14

Sentiment21

Analyst ratings1

Expectations trend26

Opinion Changes50

Price Target Upside1

Market mood51

Value Creation4/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

SK Bioscience doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Korea

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeKOSE

Employees260

Websiteskbioscience.com

ISINKR7302440003

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

Infectious DiseasesVaccinesBiopharmaBiotechnologyPharmaceutical

Description

Analysis

Middle-of-the-road

SK bioscience Co.,Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is fragile. The company scores 4/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

100

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare SK Bioscience with its peers

Sinovac Biotech

NSQ:SVA

—

CountryChina

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Handok

KSC:002390

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

GC Biopharma

KSC:006280

CountrySouth Korea

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Green Cross

KSC:005250

CountrySouth Korea

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

CSL

ASX:CSL

CountryAustralia

IndustryBiotechnology

SizeX-Large

Full Stock Analysis →

Hanmi Pharmaceutical

KSC:128940

CountrySouth Korea

IndustryPharmaceuticals

SizeMedium

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →